Article
Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity.
Immunologic research - 1 Apr 2016
García-Muñoz Ricardo, López-Díaz-de-Cerio Ascensión, Feliu Jesus, Panizo Angel, Giraldo Pilar, Rodríguez-Calvillo Mercedes, Grande Carlos, Pena Esther, Olave Mayte, Panizo Carlos, Inogés Susana
Abstract excerpt
Follicular lymphoma (FL) is a disease of paradoxes-incurable but with a long natural history. We hypothesized that a combination of lymphokine-activated killer (LAK) cells and monoclonal antibodies might provide a robust synergistic treatment and tested this hypothesis in a phase II clinical trial (NCT01329354). In this trial, in addition to R-CHOP, we alternated the administration of only rituximab with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.